Palisade Bio (PALI) EBITDA Margin (2011 - 2023)

Palisade Bio (PALI) has 11 years of EBITDA Margin data on file, last reported at 1011.6% in Q1 2023.

• EBITDA Margin for Q1 2023 came in at 1011.6%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was 5228.0% (changed N/A YoY), and the FY2023 annual result was 5228.0%, changed N/A from the prior year.
• EBITDA Margin improved to 1011.6% in Q1 2023 per PALI's latest filing, from 176623.48% in the prior quarter.
• Over five years, EBITDA Margin peaked at 1011.6% in Q1 2023 and troughed at 176623.48% in Q4 2020.
• A 3-year average of 85473.82% and a median of 81444.8% in 2019 frame the typical range for EBITDA Margin.
• The sharpest annual moves came in 2019 and 2020: EBITDA Margin soared 252640 bps in 2019, then sank 9517868 bps in 2020.
• A 3-year view of EBITDA Margin shows it stood at 81444.8% in 2019, then sank by 117 bps to 176623.48% in 2020, then surged by 99 bps to 1011.6% in 2023.
• Business Quant data shows PALI's EBITDA Margin at 1011.6% in Q1 2023, 176623.48% in Q4 2020, and 92745.68% in Q3 2020.